Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, T&C*
Uveitis Treatment Market by Drug Class (Anti-inflammatory, Antimicrobial Drugs, Immunotherapy & Targeted Therapies, and Others), Disease Type (Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis, and Panuveitis), and Distribution Channel (Hospital Pharmacy, Drug Store & Retail Pharmacy, and Online Providers): Global Opportunity Analysis and Industry Forecast, 2019–2026 Update Available On-Demand
| A05994 | Pages: 261 | Feb 2020 | 3204 Views | | |
| Author(s) : Sayali Shinde , Onkar Sumant | Tables: 114 | Charts: 53 | Formats*: | |
COVID-19
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Uveitis Treatment Market
Request Now !The global uveitis treatment market was valued at $478 million in 2018, and is projected to reach $687 million by 2026, registering a CAGR of 4.6% from 2019 to 2026.
Uveitis is the inflammation of the middle layer of tissue in the eye wall uvea that consists of the iris, choroid, and ciliary body. Different forms of drug such as cycloplegic agents, anti-inflammatory, antimicrobial drugs, immunotherapy & targeted therapies, and others are used in treatment of uveitis. Different types of uveitis include anterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis. The most common type of uveitis is an inflammation of the iris called iritis or anterior uveitis.
Get more information on this report : Request Sample Pages
Increase in prevalence of uveitis and rise in awareness among patient population with increase in adoption of advanced therapeutics is expected to drive the uveitis treatment market growth. In addition, easy accessibility to uveitis therapeutics, rise in demand for uveitis medications, and surge in R&D activities to develop ideal uveitis therapeutics further fuel the market growth. However, unknown etiology and pathophysiology of uveitis is anticipated to hamper the market growth. Furthermore, untapped potential offered by developing economies present lucrative opportunities for the growth of the market during the forecast period. However, lack of specific treatment for uveitis disorder is expected to restrain the growth of the market.
Uveitis Treatment Market Segmentation
The global uveitis treatment market is segmented on the basis of drug class, disease type, distribution channel, and region. Based on drug class, the market is classified into anti-inflammatory, antimicrobial drugs, immunotherapy & targeted therapies, and others. Disease type such as anterior uveitis, posterior uveitis, intermediate uveitis, and panuveitis are covered in the report. According to distribution channel, the market is categorized into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Segment Review
Based on drug class, the uveitis treatment market is categorized into anti-inflammatory, antimicrobial drugs, immunotherapy & targeted therapies, and others. Currently, anti-inflammatory is major revenue contributing segment and is estimated to significantly grow during the forecast period, owing to adoption of anti-inflammatory as first line treatment for uveitis.
Uveitis Treatment Market
By Drug Class
immunotherapy & targeted therapies is projected as one of the most lucrative segment.
Get more information on this report : Request Sample Pages
Anti-inflammatory medications are available in the form of eye drops, tablets, or injection form. Eye drops of anti-inflammatory drugs may not penetrate well to the back of the eye, thus this type of treatment is not preferred in posterior uveitis. In case of intermediate or posterior uveitis, and if topical corticosteroid hasn’t worked, corticosteroid injections or shot are used to reduce inflammation. On the other hand, immunotherapy & targeted therapies segment is expected to witness fastest market growth due to rise in demand for ideal therapeutics for treatment of uveitis. Immunosuppressant drugs such as azathioprine, cyclosporine, methotrexate, mycophenolate, and others are available in the uveitis treatment market.
According to disease type, the market is classified into anterior uveitis, posterior uveitis, intermediate uveitis, and panuveitis. The anterior uveitis segment is anticipated to depict a significant growth during the forecast period due to higher prevalence of uveitis. Anterior uveitis is most common type of uveitis characterized by an inflammation of the middle layer of the eye, it includes the iris and the adjacent tissue, known as the ciliary body.
Uveitis Treatment Market
By Disease Type
Anterior Uveitis holds a dominant position in 2018 and would continue to maintain the lead over the forecast period.
Get more information on this report : Request Sample Pages
Snapshot of Asia-Pacific Uveitis Treatment Market
Asia-Pacific presents lucrative opportunities for the key players operating in the uveitis treatment market, owing to growth in awareness regarding uveitis treatment and rise in adoption of uveitis treatment products. Moreover, improvement in healthcare infrastructure, rise in number of target population, developing R&D sector, rise in healthcare reforms, and technological advancements in the field of healthcare further contribute to the market growth. In addition, factors such as surge in focus of leading manufacturers on expanding their geographic presence in emerging Asia-Pacific countries to capture high growth opportunities in the marketand high population base are also expected to drive the growth of the uveitis treatment market in Asia-Pacific.
Uveitis Treatment Market
By Geography
Asia-Pacific region would exhibit the highest CAGR of 6.0% during 2019-2026.
Get more information on this report : Request Sample Pages
The key players profiled in this report include AbbVie Inc., Alimera Sciences, Inc., Allergan Plc., Amgen Inc., Bausch Health Companies Inc. (Bausch & Lomb Incorporated), Clearside Biomedical, Inc., EyePoint Pharmaceuticals, Inc., Mylan N.V., Novartis AG, and Santen Pharmaceutical Co., Ltd.
Key Benefits for Stakeholders:
- The study provides an in-depth analysis of the uveitis treatment market size along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers uveitis treatment market analysis from 2018 to 2026, which is expected to enable stakeholders to capitalize the prevailing opportunities in the market.
- A comprehensive analysis of four major regions is provided to determine the prevailing opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and global uveitis treatment market growth.
Key Market Segments:
By Drug Class
- Anti-inflammatory
- Antimicrobial Drugs
- Immunotherapy & Targeted Therapies
- Others
By Disease Type
- Anterior Uveitis
- Posterior Uveitis
- Intermediate Uveitis
- Panuveitis
By Distribution Channel
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Providers
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. Key findings
2.2.1. Top investment pockets
2.2.2. Market player positioning, 2018
2.3. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key forces shaping uveitis treatment industry/market
3.2.1. Moderate power of suppliers
3.2.2. High threat of new entrants
3.2.3. High threat of substitution
3.2.4. Moderate competitive rivalry
3.2.5. Moderate bargaining power of buyers
3.3. Market dynamics
3.3.1. Drivers
3.3.1.1. Increase in prevalence of uveitis
3.3.1.2. Potential drugs in pipeline
3.3.1.3. Surge in healthcare expenditure worldwide
3.3.2. Restraint
3.3.2.1. Unknown etiology of uveitis
3.3.3. Opportunities
3.3.3.1. Growth opportunities in emerging markets
3.3.3.2. Higher number of unmet needs for treatment of uveitis
3.3.4. Impact analysis
CHAPTER 4: UVEITIS TREATMENT MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Anti-inflammatory
4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Antimicrobial drugs
4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Immunotherapy & targeted therapies
4.4.1. Key market trends and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Others
4.5.1. Key market trends and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
CHAPTER 5: UVEITIS TREATMENT MARKET, BY DISEASE TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Anterior uveitis
5.2.1. Market size and forecast
5.2.2. Market analysis, by country
5.3. Posterior uveitis
5.3.1. Market size and forecast
5.3.2. Market analysis, by country
5.4. Intermediate uveitis
5.4.1. Market size and forecast
5.4.2. Market analysis, by country
5.5. Panuveitis
5.5.1. Market size and forecast
5.5.2. Market analysis, by country
CHAPTER 6: UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals pharmacies
6.2.1. Market size and forecast
6.2.2. Market analysis, by country
6.3. Drug stores and retail pharmacies
6.3.1. Market size and forecast
6.3.2. Market analysis, by country
6.4. Online pharmacies
6.4.1. Market size and forecast
6.4.2. Market analysis, by country
CHAPTER 7: UVEITIS TREATMENT MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by country
7.2.2.1. U.S.
7.2.2.1.1. U.S. uveitis treatment market, by drug class
7.2.2.1.2. U.S. uveitis treatment market, by disease type
7.2.2.1.3. U.S. uveitis treatment market, by distribution channel
7.2.2.2. Canada
7.2.2.2.1. Canada uveitis treatment market, by drug class
7.2.2.2.2. Canada uveitis treatment market, by disease type
7.2.2.2.3. Canada uveitis treatment market, by distribution channel
7.2.2.3. Mexico
7.2.2.3.1. Mexico uveitis treatment market, by drug class
7.2.2.3.2. Mexico uveitis treatment market, by disease type
7.2.2.3.3. Mexico uveitis treatment market, by distribution channel
7.2.3. North America market size and forecast, by drug class
7.2.4. North America uveitis treatment market, by disease type
7.2.5. North America uveitis treatment market, by distribution channel
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by country
7.3.2.1. Germany
7.3.2.1.1. Germany uveitis treatment market, by drug class
7.3.2.1.2. Germany uveitis treatment market, by disease type
7.3.2.1.3. Germany uveitis treatment market, by distribution channel
7.3.2.2. France
7.3.2.2.1. France uveitis treatment market, by drug class
7.3.2.2.2. France uveitis treatment market, by disease type
7.3.2.2.3. France uveitis treatment market, by distribution channel
7.3.2.3. UK
7.3.2.3.1. UK uveitis treatment market, by drug class
7.3.2.3.2. UK uveitis treatment market, by disease type
7.3.2.3.3. UK uveitis treatment market, by distribution channel
7.3.2.5. Italy
7.3.2.5.1. Italy uveitis treatment market, by drug class
7.3.2.5.2. Italy uveitis treatment market, by disease type
7.3.2.5.3. Italy uveitis treatment market, by distribution channel
7.3.2.6. Spain
7.3.2.6.1. Spain uveitis treatment market, by drug class
7.3.2.6.2. Spain uveitis treatment market, by disease type
7.3.2.6.3. Spain uveitis treatment market, by distribution channel
7.3.2.7. Rest of Europe
7.3.2.7.1. Rest of Europe uveitis treatment market, by drug class
7.3.2.7.2. Rest of Europe uveitis treatment market, by disease type
7.3.2.7.3. Rest of Europe uveitis treatment market, by distribution channel
7.3.3. Europe market size and forecast, by drug class
7.3.4. Europe uveitis treatment market, by disease type
7.3.5. Europe uveitis treatment market, by distribution channel
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by country
7.4.2.1. Japan
7.4.2.1.1. Japan uveitis treatment market, by drug class
7.4.2.1.2. Japan uveitis treatment market, by disease type
7.4.2.1.3. Japan uveitis treatment market, by distribution channel
7.4.2.2. China
7.4.2.2.1. China uveitis treatment market, by drug class
7.4.2.2.2. China uveitis treatment market, by disease type
7.4.2.2.3. China uveitis treatment market, by distribution channel
7.4.2.3. Australia
7.4.2.3.1. Australia uveitis treatment market, by drug class
7.4.2.3.2. Australia uveitis treatment market, by disease type
7.4.2.3.3. Australia uveitis treatment market, by distribution channel
7.4.2.5. India
7.4.2.5.1. India uveitis treatment market, by drug class
7.4.2.5.2. India uveitis treatment market, by disease type
7.4.2.5.3. India uveitis treatment market, by distribution channel
7.4.2.6. South Korea
7.4.2.6.1. South Korea uveitis treatment market, by drug class
7.4.2.6.2. South Korea uveitis treatment market, by disease type
7.4.2.6.3. South Korea uveitis treatment market, by distribution channel
7.4.2.7. Rest of Asia-Pacific
7.4.2.7.1. Rest of Asia-Pacific uveitis treatment market, by drug class
7.4.2.7.2. Rest of Asia-Pacific uveitis treatment market, by disease type
7.4.2.7.3. Rest of Asia-Pacific uveitis treatment market, by distribution channel
7.4.3. Asia-Pacific market size and forecast, by drug class
7.4.4. Asia-Pacific uveitis treatment market, by disease type
7.4.5. Asia-Pacific uveitis treatment market, by distribution channel
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. Market size and forecast, by country
7.5.2.1. Brazil
7.5.2.1.1. Brazil uveitis treatment market, by drug class
7.5.2.1.2. Brazil uveitis treatment market, by disease type
7.5.2.1.3. Brazil uveitis treatment market, by distribution channel
7.5.2.3. Saudi Arabia
7.5.2.3.1. Saudi Arabia uveitis treatment market, by drug class
7.5.2.3.2. Saudi Arabia uveitis treatment market, by disease type
7.5.2.3.3. Saudi Arabia uveitis treatment market, by distribution channel
7.5.2.4. South Africa
7.5.2.4.1. South Africa uveitis treatment market, by drug class
7.5.2.4.2. South Africa uveitis treatment market, by disease type
7.5.2.4.3. South Africa uveitis treatment market, by distribution channel
7.5.2.5. Rest of LAMEA
7.5.2.5.1. Rest of LAMEA uveitis treatment market, by drug class
7.5.2.5.2. Rest of LAMEA uveitis treatment market, by disease type
7.5.2.5.3. Rest of LAMEA uveitis treatment market, by distribution channel
7.5.3. LAMEA market size and forecast, by drug class
7.5.4. LAMEA uveitis treatment market, by disease type
7.5.5. LAMEA uveitis treatment market, by distribution channel
CHAPTER 8: COMPANY PROFILES
8.1. AbbVie Inc.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.2. Alimera Sciences, Inc.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. Allergan Plc.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.4. Amgen Inc.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments
8.5. Bausch Health Companies Inc. (Bausch & Lomb Incorporated)
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.6. Clearside Biomedical, Inc.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Product Portfolio
8.6.4. Business performance
8.7. EyePoint Pharmaceuticals, Inc.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Product Portfolio
8.7.4. Key strategic moves and developments
8.8. Mylan N.V.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. Novartis AG
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. Santen Pharmaceutical Co., Ltd.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Product portfolio
8.10.4. Business performance
LIST OF TABLES
TABLE 01. GLOBAL UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026 ($MILLION)
TABLE 02. ANTI-INFLAMMATORY MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 03. ANTIMICROBIAL DRUGS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 04. IMMUNOTHERAPY AND TARGETED THERAPIES MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 05. OTHERS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 06. GLOBAL UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026 ($MILLION)
TABLE 07. ANTERIOR UVEITIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 08. POSTERIOR UVEITIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 09. INTERMEDIATE UVEITIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 10. PANUVEITIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 11. GLOBAL UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026 ($MILLION)
TABLE 12. UVEITIS TREATMENT MARKET FOR HOSPITALS PHARMACIES, BY REGION, 2018–2026 ($MILLION)
TABLE 13. UVEITIS TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2018–2026 ($MILLION)
TABLE 14. UVEITIS TREATMENT MARKET FOR ONLINE PHARMACIES, BY REGION, 2018–2026 ($MILLION)
TABLE 15. UVEITIS TREATMENT MARKET REVENUE, BY REGION, 2018–2026 ($MILLION)
TABLE 16. NORTH AMERICA UVEITIS TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 17. U.S. UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 18. U.S. UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 19. U.S. UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 20. CANADA UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 21. CANADA UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 22. CANADA UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 23. MEXICO UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 24. MEXICO UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 25. MEXICO UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 26. NORTH AMERICA UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 27. NORTH AMERICA UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 28. NORTH AMERICA UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 29. EUROPE UVEITIS TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 30. GERMANY UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 31. GERMANY UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 32. GERMANY UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 33. FRANCE UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 34. FRANCE UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 35. FRANCE UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 36. UK UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 37. UK UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 38. UK UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 39. ITALY UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 40. ITALY UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 41. ITALY UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 42. SPAIN UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 43. SPAIN UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 44. SPAIN UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 45. REST OF EUROPE UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 46. REST OF EUROPE UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 47. REST OF EUROPE UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 48. EUROPE UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 49. EUROPE UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 50. EUROPE UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 51. ASIA-PACIFIC UVEITIS TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 52. JAPAN UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 53. JAPAN UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 54. JAPAN UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 55. CHINA UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 56. CHINA UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 57. CHINA UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 58. AUSTRALIA UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 59. AUSTRALIA UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 60. AUSTRALIA UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 61. INDIA UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 62. INDIA UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 63. INDIA UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 64. SOUTH KOREA UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 65. SOUTH KOREA UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 66. SOUTH KOREA UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 67. REST OF ASIA-PACIFIC UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 68. REST OF ASIA-PACIFIC UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 69. REST OF ASIA-PACIFIC UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 70. ASIA-PACIFIC UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 71. ASIA-PACIFIC UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 72. ASIA-PACIFIC UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 73. LAMEA UVEITIS TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 74. BRAZIL UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 75. BRAZIL UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 76. BRAZIL UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 77. SAUDI ARABIA UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 78. SAUDI ARABIA UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 79. SAUDI ARABIA UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 80. SOUTH AFRICA UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 81. SOUTH AFRICA UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 82. SOUTH AFRICA UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 83. REST OF LAMEA UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 84. REST OF LAMEA UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 85. REST OF LAMEA UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 86. LAMEA UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 87. LAMEA UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 88. LAMEA UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 89. ABBVIE INC: COMPANY SNAPSHOT
TABLE 90. ABBVIE INC: OPERATING SEGMENTS
TABLE 91. ABBVIE INC: PRODUCT PORTFOLIO
TABLE 92. ALIMERA: COMPANY SNAPSHOT
TABLE 93. ALIMERA: OPERATING SEGMENTS
TABLE 94. ALIMERA: PRODUCT PORTFOLIO
TABLE 95. ALLERGAN: COMPANY SNAPSHOT
TABLE 96. ALLERGAN: OPERATING SEGMENTS
TABLE 97. ALLERGAN: PRODUCT PORTFOLIO
TABLE 98. AMGEN: COMPANY SNAPSHOT
TABLE 99. AMGEN: PRODUCT SEGMENT
TABLE 100. AMGEN: PRODUCT PORTFOLIO
TABLE 101. BAUSCH & LOMB: COMPANY SNAPSHOT
TABLE 102. BAUSCH & LOMB: OPERATING SEGMENTS
TABLE 103. BAUSCH & LOMB: PRODUCT PORTFOLIO
TABLE 104. CLEARSIDE: COMPANY SNAPSHOT
TABLE 105. EYEPOINT: COMPANY SNAPSHOT
TABLE 106. EYEPOINT: PRODUCT PORTFOLIO
TABLE 107. MYLAN: COMPANY SNAPSHOT
TABLE 108. MYLAN: OPERATING SEGMENTS
TABLE 109. MYLAN: PRODUCT PORTFOLIO
TABLE 110. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 111. NOVARTIS: OPERATING SEGMENTS
TABLE 112. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 113. SANTEN: COMPANY SNAPSHOT
TABLE 114. SANTEN: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. TOP INVESTMENT POCKETS
FIGURE 02. MARKET PLAYER POSITIONING, 2018
FIGURE 03. GLOBAL UVEITIS TREATMENT MARKET SEGMENTATION
FIGURE 04. IMPACT ANALYSIS
FIGURE 05. COMPARATIVE ANALYSIS OF ANTI-INFLAMMATORY MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 06. COMPARATIVE ANALYSIS OF ANTIMICROBIAL DRUGS MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 07. COMPARATIVE ANALYSIS OF IMMUNOTHERAPY AND TARGETED THERAPIES MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 08. COMPARATIVE ANALYSIS OF OTHERS MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 09. COMPARATIVE ANALYSIS OF ANTERIOR UVEITIS TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 10. COMPARATIVE ANALYSIS OF POSTERIOR UVEITIS TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 11. COMPARATIVE ANALYSIS OF INTERMEDIATE UVEITIS TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 12. COMPARATIVE ANALYSIS OF PANUVEITIS TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 13. COMPARATIVE ANALYSIS OF UVEITIS TREATMENT MARKET FOR HOSPITALS PHARMACIES, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 14. COMPARATIVE ANALYSIS OF UVEITIS TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 15. COMPARATIVE ANALYSIS OF UVEITIS TREATMENT MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 16. U.S. UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 17. CANADA UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 18. MEXICO UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 19. GERMANY UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 20. FRANCE UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 21. UK UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 22. ITALY UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 23. SPAIN UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 24. REST OF EUROPE UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 25. JAPAN UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 26. CHINA UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 27. AUSTRALIA UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 28. INDIA UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 29. SOUTH KOREA UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 30. REST OF ASIA-PACIFIC UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 31. BRAZIL UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 32. SAUDI ARABIA UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 33. SOUTH AFRICA UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 34. REST OF LAMEA UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 35. ABBVIE INC: NET SALES, 2016–2018 ($MILLION)
FIGURE 36. ABBVIE INC: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 37. ABBVIE INC: REVENUE SHARE BY REGION, 2018(%)
FIGURE 38. ALIMERA: NET SALES, 2016–2018 ($MILLION)
FIGURE 39. ALIMERA: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 40. ALLERGAN: NET SALES, 2016–2018 ($MILLION)
FIGURE 41. ALLERGAN: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 42. AMGEN: NET SALES, 2016–2018 ($MILLION)
FIGURE 43. AMGEN: REVENUE SHARE BY REGION, 2018(%)
FIGURE 44. BAUSCH & LOMB: NET SALES, 2016–2018 ($MILLION)
FIGURE 45. BAUSCH & LOMB: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 46. BAUSCH & LOMB: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 47. MYLAN: NET SALES, 2016–2018 ($MILLION)
FIGURE 48. MYLAN: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 49. NOVARTIS: NET SALES, 2016–2018 ($MILLION)
FIGURE 50. NOVARTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 51. NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 52. SANTEN: REVENUE, 2016–2018 ($MILLION)
FIGURE 53. SANTEN: REVENUE SHARE BY REGION, 2018 (%)
Uveitis is the inflammation of the middle layer of tissue in the eye wall uvea that consists of the iris, choroid, and ciliary body. The adoption of uveitis treatment is expected to increase due to rise in number target population across the world and growth in awareness regarding advanced uveitis treatment in developing countries.
Rise in number of R&D activities for development of uveitis treatment medication, increase in popularity of advance therapy, and rise in number of target population significantly boost the growth of the uveitis treatment market. However, availability of alternate therapy and adverse effects associated with the use of uveitis therapeutics can hamper the market growth.
North America is expected to remain dominant during the forecast period due to higher number of target population with surge in use of uveitis therapeutics, early detection of the disease, and large presence of trained medical professionals. In addition, presence of advanced healthcare facilities, higher number of R&D activities to develop ideal therapeutics, and strong presence of key players supplement the growth of the market. In addition, Asia-Pacific and LAMEA are expected to offer lucrative opportunities to the key players during the forecast period due to rise in number of uveitis affected population with rise in demand for uveitis therapeutics.
Access from any device, anywhere
Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.
Download Sample
Purchase Full Report of
Uveitis Treatment Market
- Online Only
- $3,456
- Online cloud access only
- Restricted print, copy, paste & download
- Read only
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Data Pack
- $3,840
- Restricted to one authorized user
- One print only
- Available in
Excel - Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Single User
- $5,769
- Restricted to one authorized user
- One print only
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Five Users
- $6,450
- Limited to five authorized users
- Print upto five copies
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
-
Enterprise
License/PDF - $8,995
- Unlimited
within
company/enterprise - Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Library Membership
- $ 699/mo
- Published Content
E-access - Company Profiles
E-access - Newly Added Content Access
- 10 PDF
Downloads - 5 Excel Data
Pack Downloads - 250 Company Profiles PDF Downloads
-
Start reading instantly.
Buy Now
This title and over 12,000+ are available on the Avenue Library. T&C*.
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
Why Allied Market Research?
Infallible Methodology
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
Analyst Support
For complete satisfaction
Customization
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET VIEW
Targeted market view to provide pertinent information and save time of readers
Get fresh content delivered
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Why Allied Market Research?
Infallible Methodology
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
Analyst Support
For complete satisfaction
Customization
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET VIEW
Targeted market view to provide pertinent information and save time of readers